How often should lung adenocarcinoma be reviewed with targeted drugs?

Lung adenocarcinoma taking targeted drugs is generally reviewed every 3 months, the specific need to follow the doctor’s instructions.
For lung adenocarcinoma patients with stable clinical condition and targeted therapy after systemic treatment, imaging review can be conducted once every 3 months, the specific time depends on the condition and specific situation.
The items that need to be examined generally include: physical examination, imaging examination with enhanced CT of chest and abdomen, and for patients with brain and bone metastases, MRI of brain and bone scan of whole body can be examined regularly according to the doctor’s instruction.
If the patient’s clinical condition is unstable or new symptoms or worsening symptoms occur, a comprehensive review should be carried out in a timely manner.
In addition, for patients participating in clinical studies, the frequency of follow-up and means of review should strictly follow the protocol of clinical trials.